New anticancer drugs under clinical trials in Japan.
A total of 16 drugs developed in Japan are currently under Phase I or II trials. This article reviews results of some studies of these drugs. Studies included in the article are of SM-5887, MX-2, DWA2114R, and CPT-11.
Ogawa
M
M
Aichi Cancer Center, Nagoya, Japan.
Ariyoshi
Y
Y
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002945:Cisplatin / Q000031:analogs & derivatives; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007564:Japan; D009944:Organoplatinum Compounds / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C058816:DWA 2114; C053989:nedaplatin; D016190:Carboplatin; D002945:Cisplatin